Blood cancers

Isatuximab another string in the bow for management of RRMM

Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone found the addition ...

Already a member?

Login to keep reading.

© 2021 the limbic